[26055例血清胸苷激酶1在癌前/早期恶性肿瘤早期检测健康筛查中的应用]
[Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors].
作者信息
Cao Xia, Wang Yaqin, Yang Pingting, Zhou Hui, Liu Chang, Chen Zhiheng
机构信息
Health Management Center, Third Xiangya Hospital, Central South University, Changsha 410013, China.
出版信息
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 Oct;39(10):1029-34. doi: 10.11817/j.issn.1672-7347.2014.10.007.
OBJECTIVE
To determine the application of serum thymidine kinase 1 (STK1) in general health screening for early detection of premalignant/early malignant tumors.
METHODS
A cross sectional study was carried out in 26 055 health screenings from 8 centers of Changsha in 2011. The concentration of STK1 was determined by a sensitive chemiluminescent dot blot ECL assay.
RESULTS
In the elevated STK1 group 60.35% showed diseases with a higher risk of premalignant/ early cancerous progression. The positive rate of elevated STK1 (>2.0 pmol/L) was 2.61%. There was a significantly higher rate with moderate/severe type of hyperplasia of breasts and prostate with elevated STK1 than people with normal STK1 values.
CONCLUSION
STK1 may be a reliable marker for risk assessment of premalignant/early malignant tumors.
目的
确定血清胸苷激酶1（STK1）在一般健康筛查中用于早期检测癌前/早期恶性肿瘤的应用情况。
方法
2011年在长沙8个中心对26055例健康筛查进行了横断面研究。采用灵敏的化学发光斑点印迹ECL法测定STK1浓度。
结果
在STK1升高组中，60.35%表现出具有癌前/早期癌进展较高风险的疾病。STK1升高（>2.0 pmol/L）的阳性率为2.61%。STK1升高的乳腺和前列腺中度/重度增生类型的发生率显著高于STK1值正常的人群。
结论
STK1可能是癌前/早期恶性肿瘤风险评估的可靠标志物。
Zotero 插件